MOLECULAR PARTNERS AG -ADR Share Price Today: Live Updates & Key Insights

MOLECULAR PARTNERS AG -ADR share price today is $4.585, up -2.24%. The stock opened at $4.26 against the previous close of $4.6899, with an intraday high of $4.26 and low of $4.26.

MOLECULAR PARTNERS AG -ADR Share Price Chart

MOLECULAR PARTNERS AG -ADR

us-stock
To Invest in {{usstockname}}
us-stock

MOLECULAR PARTNERS AG -ADR Share Price Performance

$4.585 -0.0224(-2.24%) MOLN at 23 Mar 2026 02:19 PM Biotechnology
Lowest Today 4.26
Highest Today 4.26
Today’s Open 4.26
Prev. Close 4.6899
52 Week High 5.36
52 Week Low 3.36
Day’s Range: Low 4.26 High 4.26
52-Week Range: Low 3.36 High 5.36
1 day return -
1 Week return -
1 month return -8.4
3 month return -
6 month return +23.45
1 year return +16.53
3 year return -23.66
5 year return -76.47
10 year return -

MOLECULAR PARTNERS AG -ADR Institutional Holdings

Suvretta Capital Management, LLC 5.94

Bvf Inc 3.62

HBM Healthcare Investments AG Ord 2.44

SmartHarvest Portfolios, LLC 0.03

UBS Group AG 0.01

Fidelity Nasdaq Composite Index 0.00

Morgan Stanley - Brokerage Accounts 0.00

Bank of America Corp 0.00

EverSource Wealth Advisors, LLC 0.00

MOLECULAR PARTNERS AG -ADR Market Status

Strong Buy: 3

Buy: 0

Hold: 1

Sell: 0

Strong Sell: 0

MOLECULAR PARTNERS AG -ADR Fundamentals

Market Cap 171.48 M

PB Ratio 1.6923

PE Ratio 0.0

Enterprise Value 57.51 M

Total Assets 102.11 M

Volume 2720

MOLECULAR PARTNERS AG -ADR Company Financials

Annual Revenue FY23:8699000 8.7M, FY22:189556000 189.6M, FY21:9330000 9.3M, FY20:9344000 9.3M, FY19:20383000 20.4M

Annual Profit FY23:null 0.0M, FY22:189556000 189.6M, FY21:9330000 9.3M, FY20:9344000 9.3M, FY19:20383000 20.4M

Annual Net worth FY23:-59634000 -59.6M, FY22:117853000 117.9M, FY21:-63785000 -63.8M, FY20:-62764000 -62.8M, FY19:-36288000 -36.3M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:681000 0.7M, Q2/2024:1551000 1.6M

Quarterly Profit Q3/2025:-8327999 -8.3M, Q2/2025:-10706000 -10.7M, Q1/2025:-11921000 -11.9M, Q3/2024:681000 0.7M, Q2/2024:-11536000 -11.5M

Quarterly Net worth Q3/2025:-11836000 -11.8M, Q2/2025:-20398000 -20.4M, Q1/2025:-16771000 -16.8M, Q3/2024:-16404000 -16.4M, Q2/2024:-15082000 -15.1M

About MOLECULAR PARTNERS AG -ADR & investment objective

Company Information Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in Phase 1 clinical trial to treat SCLC and neuroendocrine tumors. It also researches for Switch-DARPin T cell engager to treat CD3 x costim x; and MP0726, a Radio-DARPin Therapy to treat ovarian cancer and other MSLNexpressing cancers. In addition, the company develops MP0621, a Switch-DARPin candidate targeting CD16a, c-KIT, and CD47 as conditioning for hematopoietic stem cell transplantation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics and an additional six targeted alpha therapeutics candidates and Eckert & Ziegler SE to develop Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

Organisation Biotechnology

Employees 134

Industry Biotechnology

CEO Dr. Patrick Amstutz Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

MOLECULAR PARTNERS AG -ADR FAQs

What is the share price of MOLECULAR PARTNERS AG -ADR today?

The current share price of MOLECULAR PARTNERS AG -ADR is $4.585.

Can I buy MOLECULAR PARTNERS AG -ADR shares in India?

Yes, Indian investors can buy MOLECULAR PARTNERS AG -ADR shares by opening an international trading and demat account with Motilal Oswal.

How to buy MOLECULAR PARTNERS AG -ADR shares in India?

You can easily invest in MOLECULAR PARTNERS AG -ADR shares from India by:

Can I buy fractional shares of MOLECULAR PARTNERS AG -ADR?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of MOLECULAR PARTNERS AG -ADR?

MOLECULAR PARTNERS AG -ADR has a market cap of $171.48 M.

In which sector does MOLECULAR PARTNERS AG -ADR belong?

MOLECULAR PARTNERS AG -ADR operates in the Biotechnology sector.

What documents are required to invest in MOLECULAR PARTNERS AG -ADR stocks?

To invest, you typically need:

What is the PE and PB ratio of MOLECULAR PARTNERS AG -ADR?

The PE ratio of MOLECULAR PARTNERS AG -ADR is N/A and the PB ratio is 1.69.